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Autoantibody against nicotinic acetylcholine receptor (nAChR) α3 subunit has been 
implicated in paraneoplastic neurological syndrome.  It has been proposed that this 
autoantibody impairs synaptic transmission, probably by inducing the internalization of 
nAChR.  To confirm this hypothesis, we incubated human embryonic kidney cells 
exogenously expressing α3 subunit with seropositive serum, and visualized the 
intracellular localization of IgG and α3 subunits by double-labeled immunofluorescence 
staining.  As a result, co-localization of internalized IgG and α3 subunits was observed 
as overlapping punctate fluorescent staining.  Our results suggest that autoantibodies 
against nAChR α3 subunit play a pathogenic role in synaptic transmission by inducing 
nAChR internalization. 
 





Autoantibody against nicotinic acetylcholine receptor (nAChR) α3 subunit has 
been implicated in paraneoplastic neurological syndrome (Vernino et al., 1998; 
McKeon et al., 2009).  This autoantibody is also known as ‘anti-ganglionic nAChR 
autoantibody’ because it was first detected as an autoantibody specific for neuronal 
nAChR expressed in autonomic ganglia (Vernino et al., 2000).  Some clinical and 
serological studies have revealed the positive correlation between serum levels of this 
autoantibody and the severity of autonomic symptoms including orthostatic hypotension, 
gastrointestinal hypomotility and sudomotor dysfunction (Klein et al., 2003; Winston 
and Vernino, 2010).  In addition, recent studies have reported the presence of diverse 
neurological symptoms unrelated to autonomic nervous systems, such as peripheral 
neuropathy and psychiatric symptoms, in seropositive patients (McKeon et al., 2009; 
Gibbons et al., 2012). 
Neuronal nAChRs are ligand-gated cation channels that mediate fast synaptic 
transmission.  They are assembled as a homomeric or heteromeric pentamer from α 
(α2-α10) and β (β2-β4) subunits (Albuquerque et al., 2009).  The α3 subunits are 
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widely distributed in both central and peripheral nervous systems (Flores et al., 1996; 
Genzen et al., 2001; Skok, 2002; Khan et al., 2003), where they are expressed in various 
combinations with α5, β2 and β4 subunits (Albuquerque et al., 2009).  The wide 
distribution of α3 subunits may explain the diversity of neurological symptoms 
observed in seropositive patients.  On the other hand, autoimmunity to α4 and α7 
subunits has been thought to be involved in some neurological disorders, such as 
encephalopathy and cognitive impairment (Baker et al., 2009; Lykhmus et al., 2011).   
There is increasing evidence that autoantibody-mediated dysfunction of nAChR is 
associated with the neurological symptoms observed in seropositive patients.  Some 
electrophysiological studies both in vivo and in vitro have revealed the pathogenic roles 
of anti-nAChR α3 subunit autoantibody.  Rabbits immunized with recombinant α3 
subunits (Lennon et al., 2003) and mice given anti-nAChR α3 subunit autoantibodies by 
passive transfer (Vernino et al., 2004; Wang et al., 2010) developed autonomic 
dysfunction and showed the impairment of cholinergic neurotransmission.  It was 
suggested that cross-linking and internalization of cell-surface nAChR mainly 
contribute to the impairment of nAChR current (Wang et al., 2007).  However, there is 
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no evidence for autoantibody-mediated internalization of α3 subunits so far.  
Therefore, we examined the internalization of IgG and the α3 subunit using a 
seropositive patient’s serum by double-labeled immunofluorescence staining.  To 
examine the specific contribution of the autoantibody to the α3 subunits, we carried out 
experiments on human embryonic kidney (HEK) 293 cells stably co-expressing α3 and 
β4 subunits.  The seropositive patient’s serum used in this study was confirmed to 
include IgG specifically recognizing the α3 subunit.  This study reinforces the idea 
that autoantibody against neuronal nAChR contributes to pathogenic processes by 




2. Materials and methods 
2.1. Serum samples 
Serum was collected from a patient with paraneoplastic neurological disorder who 
was seropositive for anti-ganglionic nAChR autoantibody.  The titer of the 
autoantibody was estimated to be 2.20 nmol/L (normal<0.05 nmol/L) by the 
radioimmunoprecipitation assay described in a previous report (Vernino et al., 2008).  
Three samples of normal sera were obtained from healthy volunteers who received an 
annual health checkup at Keiju Medical Center (Nanao, Japan).  Informed consent for 
this study was obtained from all subjects.  This study was performed under the 
approval of the Medical Ethics Committee of Kanazawa University. 
 
2.2. Construction of expression plasmids 
cDNA fragments encoding human nAChR α3, α4, α5, α7, β2 and β4 subunits 
were obtained by reverse transcription-polymerase chain reaction (RT-PCR) as follows.  
Human brain total RNA (Clontech, Mountain View, CA, USA) was reverse-transcribed 
using Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, 
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Mannheim, Germany) according to the manufacturer’s protocol.  The resulting cDNA 
was then subjected to nested PCR using two sets of primers specific for each subunit 
(Table 1).  Each reaction mixture (50 µl) contained cDNA (corresponding to 10 ng of 
total RNA), KOD FX buffer (Toyobo, Osaka, Japan), 200 µM dNTPs, 300 nM each 
primer and KOD FX DNA polymerase (Toyobo).  Amplification was carried out in a 
thermal cycler (Applied Biosystems, Foster City, CA, USA) with the following 
protocol: initial denaturation at 96°C for 1 min, followed by 30 cycles of 10 sec at 98°C, 
30 sec at 65°C and 2 min at 68°C.  The resulting PCR products were purified using 
MinElute PCR Purification Kit (QIAGEN, Hilden, Germany).  After addition of 
deoxyadenosine to the 3' ends using Ex Taq polymerase (Takara Shuzo, Otsu, Japan), 
the cDNA fragments encoding nAChR α3, α4, α5, α7, β2 and β4 subunits were cloned 
into a pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) using a TOPO TA 
Cloning Kit (Invitrogen) according to the manufacturer’s protocol, to yield 
pTOPO-CHRNA3, pTOPO-CHRNA4, pTOPO-CHRNA5, pTOPO-CHRNA7, 
pTOPO-CHRNB2 and pTOPO-CHRNB4, respectively.  The cDNA inserts were 
verified by nucleotide sequencing.  The 1.5-kb EcoRI fragments from 
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pTOPO-CHRNA3 and pTOPO-CHRNB4 were cloned into the EcoRI site of pcDNA3.1 
(+) (Invitrogen); the resulting plasmids were designated pcDNA-CHRNA3 and 
pcDNA-CHRNB4, respectively.  In addition, the 1.5-, 1.9-, 1.5-, 1.5- and 1.5-kb 
EcoRI fragments from pTOPO-CHRNA3, pTOPO-CHRNA4, pTOPO-CHRNA5, 
pTOPO-CHRNB2 and pTOPO-CHRNB4, respectively, and the 1.5-kb XhoI/BamHI 
fragments from pTOPO-CHRNA7 were ligated to the XbaI-cleaved pEF-BOS (a 
generous gift from Professor Nagata, Kyoto University, Japan) (Mizushima and Nagata, 
1990), after treatment with Klenow fragment of DNA polymerase I; likewise, the 
resulting plasmids were designated pEF-CHRNA3, pEF-CHRNA4, pEF-CHRNA5, 
pEF-CHRNA7, pEF-CHRNB2 and pEF-CHRNB4, respectively. 
 
2.3. Cell culture and transfection 
HEK293 cells were maintained in a humidified incubator with 5% CO2 at 37°C in 
Dulbecco’s modified Eagle’s medium (DMEM; Wako Pure Chemical Industries, Osaka, 
Japan) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco-BRL, 
Grand Island, NY, USA), 100 units/ml penicillin and 0.1 mg/ml streptomycin (Wako 
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Pure Chemical Industries). 
For transient transfection, COS-7 cells were seeded at a density of 1.0 x 104 
cells/cm2 on poly-L-ornithine (PLO; Sigma-Aldrich, St. Louis, MO, USA)-coated glass 
coverslips or 100-mm culture dishes.  Twenty-four hours after seeding, cells were 
transiently transfected with pEF-CHRNA3, pEF-CHRNA4, pEF-CHRNA5, 
pEF-CHRNA7, pEF-CHRNB2, pEF-CHRNB4 and empty vector (mock) using 
FuGENE6 Transfection Reagent (Roche Applied Science) according to the 
manufacturer’s protocol.  Forty-eight hours after transfection, cells were subjected to 
autoantibody detection by immunofluorescence staining and immunoblot analysis. 
For stable transfection, HEK293 cells were seeded at a density of 1.0 x 104 
cells/cm2 on 100-mm culture dishes.  Forty-eight hours after seeding, cells were 
co-transfected with pcDNA-CHRNA3 and pcDNA-CHRNB4, or transfected with an 
empty vector (mock) using FuGENE6 Transfection Reagent.  Forty-eight hours after 
transfection, culture medium was replaced with DMEM containing 10% FBS and 800 
µg/ml G418 (Roche Applied Science).  Cell colonies resistant to G418 were isolated 
and maintained in DMEM containing 10% FBS and 100 µg/ml G418.  Co-expression 
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of α3 and β4 subunits was confirmed by both immunofluorescence staining and 
immunoblot analysis. 
 
2.4. Immunofluorescence staining 
COS-7 and HEK293 cells were grown on PLO-coated glass coverslips, fixed in 
ice-cold 4% paraformaldehyde (PFA) for 20 min, washed in PBS, three changes, each 
10 min, blocked in PBS containing 1% BSA and 0.3% Triton X-100 for 30 min and 
sequentially incubated with (1) primary antibodies against each nAChR subunit (Table 
2) in the blocking solution for 3 hr at room temperature (RT); (2) washing solution 
(PBS containing 0.3% Triton X-100), three changes, each 10 min; (3) secondary 
antibodies (Table 2) in the blocking solution for 1 hr at RT; and (4) washing solution, 
three changes, each 10 min.  For staining of cell-surface nAChR subunits, Triton 
X-100 was omitted from all solutions.  In the case of autoantibody detection, COS-7 
cells were first incubated with the patient’s or normal serum (1:500-10,000) overnight 
at 4°C, and then with secondary antibody (Table 2) for 1 hr at RT.  The coverslips 
were mounted on glass slides with Dapi-Fluoromount-G (SouthernBiotech, 
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Birmingham, AL, USA).  Images were captured by a BX51 fluorescence microscope 
(Olympus, Tokyo, Japan) using DP controller (Olympus) and processed using DP 
Manager (Olympus).  Fluorescence Mirror Units were U-MNIBA3 (excitation, 
470−495 nm; emission, 510−550 nm), U-MWIG3 (excitation, 530−550 nm; emission, 
575 nm) and U-MWU2 (excitation, 330−385 nm; emission, 420 nm).  
Immunofluorescent intensities were quantitated densitometrically using ImageJ 
software (version 1.43; National Institute of Health, Bethesda, MD, USA).  The ratio 
of red (Alexa Fluor 594) to green (DyLight 488) fluorescent signals was calculated after 
subtracting green fluorescent intensities obtained from non-transfected COS-7 cells.  
One hundred and eighty cells were analyzed in twenty-eight random fields obtained 
from two independent experiments. 
 
2.5. Immunoblot analysis 
COS-7 and HEK293 cells on culture plates were harvested by scraping in PBS 
containing 0.1% (w/v) EDTA and pelleted by centrifugation at 1,500 × g for 5 min at 
4°C.  The pellets were homogenized in ice-cold homogenization solution containing 
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0.32 M sucrose, 2 mM EDTA, 2 mM EGTA, 20 mM HEPES and protease inhibitor 
cocktail (BioVision Research Products, Milpitas, CA, USA) at pH 7.2 using a Dounce 
homogenizer.  Protein concentration of homogenates was determined using DC protein 
assay (BIO-RAD, Hercules, CA, USA).  The homogenates were solubilized in 
Laemmli sample buffer, subjected to 10% SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred onto polyvinylidene difluoride membranes (Millipore, 
Billerica, MA, USA).  Then, the blots were blocked in TBS containing 3% BSA and 
0.04% NP-40 for 1 hr and sequentially incubated in (1) primary antibody (Table 2) or 
serum (1:100) in antibody-incubation solution (TBS containing 1% BSA and 0.04% 
NP-40) overnight at 4°C; (2) washing solution (TBS containing 0.04% NP-40), three 
changes, each 15 min; (3) secondary antibodies (Table 2) in antibody-incubation 
solution for 1 hr at RT; and (4) washing solution, three changes, each 15 min.  The 
blots were developed using AP color development reagent (BIO-RAD). 
 
2.6. Assay for antibody-mediated internalization of nAChR α3 subunit  
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HEK293 cells stably co-expressing α3 and β4 subunits (HEK293-α3β4) and 
mock-transfected cells were seeded at a density of 5.0 x 104 cells/cm2 on PLO-coated 
glass coverslips in a 24-well culture plate.  On the second day, the cells were washed 
in PBS and incubated with heat-inactivated serum (5%) or rat anti-nAChR α3 
monoclonal antibody (1 µg/ml; Abcam, Cambridge, UK) in the culture medium for 30 
min at 4°C or 37°C.  CELL LAB Rat IgG Isotype Control (Beckman Coulter, Brea, 
CA, USA) was used as a negative control for the rat anti-nAChR α3 monoclonal 
antibody.  The cells were then subjected to immunofluorescence staining using 
secondary antibody for human and rat IgG (Table 2).  For double-labeled 
immunofluorescence staining, the cells were stained with antibody against nAChR α3 
subunit and Alexa Fluor 594-conjugated secondary antibody (Table 2).  To evaluate 
the autoantibody-mediated internalization of nAChR α3 subunits, the number of 
overlapping punctate dots per cell was counted under a fluorescence microscope.  We 
counted 200 cells in eight random fields obtained from two independent experiments. 
 
2.7. Statistical analysis 
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Data are shown as mean ± S.D.  Results were compared using two-tailed t-test.  
The analyses were performed with the statistical analysis system StatMateIII (ATMS 
Co., Ltd., Tokyo, Japan). 
 
3. Results 
3.1. Detection of autoantibodies against neuronal nAChR subunit 
Using sera from a patient with paraneoplastic neurological syndrome or normal 
volunteers and commercial antibodies, we performed double-labeled 
immunofluorescence staining on COS-7 cells transiently expressing α3, α4, α5, α7, β2 
and β4 subunits (Fig. 1).  Overlapping staining of human IgG and α3 subunit was 
observed in the patient’s serum, but not in normal serum (Fig. 1A).  Fig. 1B shows the 
relationship between serial serum dilution (1:500−10,000) and relative fluorescent 
intensities of human IgG.  Reduction of relative immunofluorescent intensities was 
observed in the serial dilution of the patient’s serum, but not in that of normal serum.  
Staining of the patient’s IgG was not detected in the cells expressing α4, α5, α7, β2 and 
β4 subunits (Fig. 1C).  These results clearly suggested the presence of autoantibodies 
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against α3 subunit in the patient’s serum, but not in the normal sera. 
We also performed immunoblot analysis to examine the affinity of the patient’s 
IgG for the α3 subunit (Fig. 2).  We confirmed the expression of α3 subunit in COS-7 
cells using commercial antibody.  Two main protein bands with predicted molecular 
masses of 50 kD and 55 kD were detected in the COS-7 cells transfected with 
pEF-CHRNA3, but not in the mock-transfected cells (Fig. 2A).  In the patient’s serum, 
a similar blot pattern of recognition was found with anti-human IgG3 antibody, but not 
with anti-human IgG1, 2 and 4 antibodies (Fig. 2B). 
  
3.2. Stable co-expression of nAChR α3 and β4 subunits in HEK293 cells 
To examine the autoantibody-mediated internalization of α3 subunit, we 
established HEK293 cells stably co-expressing α3 and β4 subunits (HEK293-α3β4).  
We confirmed the co-expression of both subunits by immunoblot analysis and 
immunofluorescence staining (Fig. 3).  Fig. 3A shows the result of immunoblot 
analysis.  The predicted bands of α3 (50 kD) and β4 (55 kD) were detected in 
HEK293-α3β4 cells, but not in mock-transfected cells.  The band at 42 kD is most 
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likely a proteolytic form of β4 subunit.  The bands at 38 kD and 70 kD might be 
non-specific reactions of anti-nAChR β4 antibody because these bands were also seen 
in mock-transfected cells.  To detect the co-expression of α3 and β4 subunits on the 
cell surface, we performed immunofluorescence staining under non-permeable 
conditions using specific antibodies recognizing the extracellular epitope of α3 or β4 
subunit.  Immunoreactivities of α3 and β4 subunits were clearly detected in 
HEK293-α3β4 cells, but not in mock-transfected cells (Fig. 3B). 
 
3.3. Autoantibody-mediated internalization of cell-surface nAChR α3 subunits 
To assess the autoantibody-mediated internalization of cell-surface α3 subunits, 
we incubated HEK293-α3β4 cells with the patient’s heat-inactivated serum at 4°C or 
37°C.  After 30-min incubation at 4°C, IgG was distributed uniformly over the cells 
(Fig. 4A).  In contrast, after 30-min incubation at 37°C, IgG was detected as punctate 
dots (Fig. 4B).  When the cells were incubated with rat anti-nAChR α3 monoclonal 
antibodies (rat anti-α3) as a positive control, the formation of punctate dots of rat IgG 
occurred in a temperature-dependent manner, as seen for the patient’s IgG (Fig. 4D and 
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E).  Only a few punctate dots were seen under non-permeable staining conditions (data 
not shown), suggesting the internalization and intracellular localization of the patient’s 
and rat IgG.  Internalization of IgG was α3 subunit-specific because no punctate dots 
were seen in mock-transfected cells incubated with both the patient’s serum and rat 
anti-α3 (Fig. 4C and F).  Punctate dots were not seen in the HEK293-α3β4 cells 
incubated with normal serum (Fig. 5A). 
Furthermore, we performed double-labeled immunofluorescence staining to 
examine the co-localization of internalized IgG and the α3 subunit (Fig. 5).  The α3 
subunit was stained using rabbit anti-nAChR α3 antibody that recognizes different 
epitopes of rat anti-α3.  To test the time-dependent effect of IgG on α3 subunit 
internalization, we compared the formation of overlapping staining at 5 min and 30 min 
after incubation.  As observed in Fig. 4B and E, internalized patient’s and rat IgG were 
detected as punctate dots.  The α3 subunits were also stained as a punctate pattern and 
overlapped with each IgG.  The formation of overlapping punctate dots was observed 
in a time-dependent manner (Fig. 5A).  Fig. 5B shows the quantitative results of 
overlapping punctate dot formation per cell at the indicated times after incubation.  
18 
 
HEK293-α3β4 cells incubated with the patient’s serum or rat anti-α3 for 5 min formed 
5.3 ± 2.4 or 5.6 ± 3.2 punctate dots (n = 50), whereas those incubated for 30 min formed 
19.0 ± 5.4 or 17.8 ± 5.7 punctate dots (n = 50), respectively (p<0.001).  When the cells 
were incubated with normal serum, no punctate dot formation of IgG was observed, and 
α3 subunits were diffusely stained over the cell.  These results clearly suggested the 
autoantibody-mediated internalization of α3 subunits. 
 
4. Discussion 
Autoantibody-mediated internalization of cell-surface antigen is now recognized 
as a key mechanism for some immune-mediated disorders, such as myasthenia gravis 
(MG) (Drachman et al., 1978), anti-N-methyl-D-aspartate receptor encephalitis (Hughes 
et al., 2010) and neuromyelitis optica (Hinson et al., 2012).  In this study, we directly 
showed the involvement of autoantibodies in the internalization of nAChR α3 subunit 
in vitro. 
In the first part of this study, we demonstrated the affinity of the patient’s IgG3 
for α3 subunit using immunofluorescence staining and immunoblot analysis.  The 
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commonly used assay for the detection of anti-nAChR α3 subunit autoantibody is 
radioimmunoprecipitation (RIP) using iodine 125 (125I)-labeled epibatidine, a potent but 
non-selective agonist for neuronal nAChR, and solubilized neuronal nAChR from 
human neuroblastoma IMR-32 cells as antigenic sources (Vernino et al., 2000).  
IMR-32 cells are confirmed to express at least six neuronal nAChR subunits: α3, α4, 
α5, α7, β2 and β4 (Groot Kormelink and Luyten, 1997).  Although autoantibodies 
detected in this RIP assay have been suggested to be highly specific for α3 subunit, 
cross-reaction between different nAChR subunits can occur (Balestra et al., 2000; 
Vernino et al., 2008; Baker et al., 2009).  In contrast, the immuofluorescence staining 
and immunoblot analysis established in this study can determine both the subunit 
specificity and the IgG subclass of the autoantibodies.  Differences in these factors of 
autoantibody could affect the diversity of clinical symptoms between seropositive 
patients.  Therefore, our assay methods may contribute to our understanding of the 
pathogenic roles of the autoantibody against neuronal nAChRs. 
In contrast to anti-nAChR α3 subunit autoantibody, pathogenic roles of 
anti-muscle nAChR autoantibodies in MG patients have been well characterized.  
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Accumulating evidence suggests that the following three effects are major contributing 
factors to MG pathogenesis (Keefe et al., 2009).  When bound to muscle nAChR, 
autoantibodies induce (1) blocking of the cholinergic neurotransmission at 
neuromuscular junction (Drachman et al., 1982), (2) cross-linking and internalization of 
the muscle nAChR (Drachman et al., 1978) and (3) complement-dependent cell damage 
(Engel et al., 1979).  On the other hand, some electrophysiological studies 
demonstrated that the anti-nAChR α3 subunit autoantibody impaired the synaptic 
transmission (Lennon et al., 2003; Vernino et al., 2004), probably by mechanisms 
involving the autoantibody-mediated blocking and/or internalization of functional 
nAChR on the cell surface as reported in MG.  In this study, we performed the assay 
for autoantibody-mediated internalization of nAChR using a seropositive patient’s 
serum.  For this assay, we established HEK293 cells stably co-expressing α3 and β4 
subunits (HEK293-α3β4 cells).  In accordance with previous reports that α3 subunits 
could form functional receptors when expressed in combination with β4 subunits on the 
HEK293 cell surface (Krashia et al., 2010), we successfully co-expressed the α3 and β4 
subunits on the surface of HEK293 cells.  When the HEK293-α3β4 cells were 
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incubated with the patient’s serum, antibody-mediated internalization of α3 subunits 
was observed within 30 min, as predicted by a previous study (Wang et al., 2007).  We 
also demonstrated the internalization of α3 subunits using rat anti-nAChR α3 
monoclonal antibody as a positive control.  This result suggests that antibodies against 
the extracellular domain of the α3 subunit can induce internalization of the cell-surface 
α3 subunit.  Internalization of antibody was remarkably inhibited at low temperature, 
indicating that autoantibodies could be internalized via endocytosis because endocytic 
membrane trafficking is inhibited at low temperature (Arancibia-Carcamo et al., 2006). 
On the other hand, it also remains to be seen whether complement-mediated 
neuronal cell damage is involved in the progression of neuronal symptoms.  Some 
recent studies suggested that long-standing exposure to anti-nAChR α3 subunit 
autoantibodies may cause the loss of neuronal cells and irreversible neuronal cell 
damage (Koike et al., 2010; Manganelli et al., 2011).  In this study, we detected the 
IgG3 subclass autoantibody, which activates complement, in the patient’s serum.  
Although we have not examined the complement-dependent cell damage, differences in 
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IgG subclasses of autoantibodies could underlie the variety of clinical symptoms in 
seropositive patients. 
In conclusion, we obtained evidence that autoantibodies against nAChR α3 
subunit induced the internalization of cell-surface nAChR.  Our results support the 
hypothesis that the internalization of cell-surface nAChR is involved in the 
pathogenesis of the autoantibody against the nAChR α3 subunit.  However, this study 
was restricted in that serum was only obtained from one seropositive patient.  Further 
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Fig. 1.  Detection of autoantibodies against neuronal nAChR subunits by 
double-labeled immunofluorescence staining.  (A) COS-7 cells transiently expressing 
α3 subunit were stained with the patient’s serum (top) and normal serum (bottom).  
IgG, human IgG detected with DyLight 488-conjugated anti-human IgG antibody 
(green); α3, commercially available anti-nAChR α3 antibody detected with Alexa Fluor 
594-conjugated anti-rabbit IgG antibody (red); Merge, merged images (yellow).  
Nuclei were stained with DAPI (blue).  Note that staining of IgG was detectable from 
the patient’s serum, but not from normal control.  (B) Relationship between serum 
dilution and relative fluorescent intensity.  Abscissa, serum dilution; ordinate, relative 
intensity.  The fluorescent intensity for human IgG (green) was normalized to that for 
nAChR α3 (red).  (C) COS-7 cells transiently expressing nAChR α4, α5, α7, β2 and 
β4 subunits were stained with the patient’s serum and commercially available 
antibodies specific for the indicated subunits as described above for α3.  Merged 
images are shown.  Note that no staining of human IgG (green) is detectable.  Scale 




Fig. 2.  Detection of anti-nAChR α3 autoantibodies by immunoblot analysis.  (A) 
Detection with rabbit anti-nAChR α3 subunit (Rabbit anti-α3).  Homogenates (1 µg of 
protein) prepared from COS-7 cells transiently transfected with pEF-CHRNA3 (α3) and 
empty vector (Mock) subjected to immunoblot analysis as described in the Materials 
and methods.  Note that two bands of 55 and 50 kD are specifically detected for 
pEF-CHRNA3-transfected cells.  (B) Detection with the patient’s serum.  Note that 
two bands of 55 and 50 kD as in (A) are detectable with anti-human IgG3 antibody, but 
not with anti-human IgG1, 2 and 4 antibodies.  The positions of molecular weight 
markers (kD) are indicated on the left. 
 
Fig. 3.  Establishment of human embryonic kidney (HEK) 293 cells stably 
co-expressing nAChR α3 and β4 subunits.  (A) Immunoblot analysis of homogenates 
(10 µg of protein) from HEK293 cells stably co-transfected with pcDNA-CHRNA3 and 
pcDNA-CHRNB4 (α3β4) and those with empty vector (Mock).  The blots were 
probed with rabbit anti-nAChR α3 antibody (Anti-α3) or rabbit anti-nAChR β4 
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antibody (Anti-β4).  The positions of molecular weight markers (kD) are indicated.  
(B) Immunofluorescence staining of HEK293-α3β4 cells (α3β4) and mock-transfected 
cells (Mock).  Cells were stained with rat anti-nAChR α3 (Anti-α3) and rabbit 
anti-nAChR β4 (Anti-β4) under non-permeable staining conditions, and detected with 
Alexa Fluor 488-conjugated anti-rat IgG antibody (green) and Alexa Fluor 
594-conjugated anti-rabbit IgG antibody (red), respectively.  Nuclei were stained with 
DAPI (blue).  Scale bar, 100 µm. 
 
Fig. 4.  Detection of internalized human and rat IgG in HEK293 cells stably 
co-expressing nAChR α3 and β4 subunits by immunofluorescence staining.  HEK293 
cells stably expressing both α3 and β4 subunits (HEK293-α3β4) and mock-transfected 
cells (Mock) were incubated with the patient’s serum (A−C) or rat anti-nAChR α3 
monoclonal antibody (Rat anti-α3; D−F) for 30 min at 4°C or 37°C.  Cells were then 
fixed, permeabilized and stained with DyLight 488-conjugated anti-human IgG 
antibody (A−C) or Alexa Fluor 488-conjugated anti-rat IgG antibody (D−F).  Note that 
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punctate staining of both patient’s and rat IgG is detectable in HEK293-α3β4 cells at 
37°C, but not at 4°C.  Scale bar, 20 µm. 
 
Fig. 5.  Co-localization of internalized human and rat IgG with nAChR α3 subunit in 
HEK293 cells stably co-expressing α3 and β4 subunits (HEK293-α3β4).  (A) Cells 
were incubated with the patient’s serum, normal control serum or rat anti-nAChR α3 
monoclonal antibody (Rat anti-α3) for 5 min and 30 min at 37°C.  Then, the cells were 
fixed, permeabilized and stained with rabbit anti-nAChR α3 antibody, followed by 
detection with DyLight 488-conjugated anti-human IgG or Alexa Fluor 488-conjugated 
anti-rat IgG (green), and Alexa Fluor 488-conjugated anti-rabbit IgG (red).  Nuclei 
were stained with DAPI (blue).  Scale bar, 20 µm.  (B) The number of overlapping 
punctate dots formed by patient’s serum and rat anti-α3 was counted at the indicated 
time points.  Data are expressed as mean ± S.D.; *, p<0.001, two-tailed t-test.  Note 
that overlapping punctate dots were observed in the cells incubated with the patient’s 
serum and rat anti-α3, and increased in a time-dependent manner.  No overlapping 




Primers used for amplification of cDNAs encoding human nAChR subunits 
Subunit  Sequence (5′–3′) 
α3   F1: ggtctggggtctgcgctgga         F2: gagaggccgtctctgcgacc 
R1: gaagcagcctcctcctgccc         R2: ggcaggcacacagcttagtgc 
α4   F1: cccacaggagaagacgaac         F2: catctagagcccgcgaggtg 
R1: ccaaggccgtcttacagcag         R2: gagtccagggagaagccagc 
α5   F1: cacgactcacactcagtgctc         F2: aagagttcgcgttccccgcg 
R1: ataggtgccatcagatatatgtgtg        R2: acttcagtcccttgggaggc 
α7   F1: gcgacagccgagacgtggag        F2: gctgcagctccgggactcaa 
 R1: gtggcgtgtaatgctgtcctgg        R2: ggccttgcccatctgtgagt 
β2  F1: ggcttcagcaccacggacag        F2: ggtgtaggcgaggcagcgag 
  R1: gcccctcttcctggtagctc         R2: tactgtgcagcagagggtggc 
β4   F1: aggaccggcgctcactcgac        F2: tgtgaccccacagcggagct 
R1: gggcctcatcagccacaacc        R2: ctctcaccccacaacccagg 
 





Table 2. List of antibodies used in this study 
 
Antibody   Species / Clonality Source (Catalogue No.)     Dilution           Usage 
 
Primary antibodies 
Anti-nAChR α3 subunit          Rabbit / Polyclonal  Santa Cruz (sc-5590)      1:1,000          IF, IB 
Anti-nAChR α4 subunit   Goat / Polyclonal Santa Cruz (sc-1772)     1:1,000          IF 
Anti-nAChR α5 subunit  Rabbit / Polyclonal Abcam (ab26099)      1:1,000          IF 
Anti-nAChR α7 subunit  Goat / Polyclonal   Santa Cruz (sc-1447)      1:1,000          IF 
Anti-nAChR β2 subunit  Rabbit / Polyclonal Santa Cruz (sc-11372)      1:1,000          IF 
Anti-nAChR β4 subunit  Rabbit / Polyclonal Millipore (AB15327)      1:2,000          IF, IB 
Anti-nAChR   Rat / Monoclonal  Abcam (ab24719)      1:1,000          IF 
α1, α3, α5 subunit 
 
Secondary antibodies 
Alexa Fluor 594-conjugated  Donkey   Invitrogen (A21207)     1:2,000          IF 
anti-rabbit IgG 
Alexa Fluor 594-conjugated Donkey   Invitrogen (A11058)     1:2,000          IF 
anti-goat IgG 
Alexa Fluor 594-conjugated  Donkey   Invitrogen (A21209)  1:2,000-5,000          IF 
 anti-rat IgG 
Alexa Fluor 488-conjugated Donkey   Invitrogen (A21206)     1:2,000          IF 
anti-rabbit IgG 
DyLight 488-conjugated   Donkey   Jackson ImmunoRes.Lab.     1:2,000          IF 
anti-human IgG                                (709-486-149) 
Alkaline-phophatase-conjugated Goat   BIO-RAD (170-6518)      1:2,000          IB 
anti-rabbit IgG  
Alkaline-phophatase-conjugated 
anti-human IgG1  Mouse   Merck KGaA (401459)      1:5,000          IB 
anti-human IgG2  Mouse   Merck KGaA (401462)      1:5,000          IB 
anti-human IgG3  Mouse   Merck KGaA (401465)      1:5,000          IB 
anti-human IgG4  Mouse   Merck KGaA (401468)      1:5,000          IB 
 
IF, immunofluorescence staining; IB, immunoblot analysis 
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